Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2012

Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain-Acetyl-lysine Interactions.

Hewings DS, Rooney TP, Jennings LE, Hay DA, Schofield CJ, Brennan PE, Knapp S, Conway SJ

J. Med. Chem.. 2012-11-26 . 55(22):9393-413 .doi: 10.1021/jm300915b

PMID: 22924434

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L

J. Med. Chem.. 2012-11-8 . 55(21):9312-30 .doi: 10.1021/jm301034u

PMID: 22998443

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN

J. Biol. Chem.. 2012-10-26 . 287(44):36990-8 .doi: 10.1074/jbc.M112.365932

PMID: 22977237

A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B.

De Antoni A, Maffini S, Knapp S, Musacchio A, Santaguida S

J. Cell Biol.. 2012-10-15 . 199(2):269-84 .doi: 10.1083/jcb.201205119

PMID: 23071153

Crystal structure of human aurora B in complex with INCENP and VX-680.

Elkins JM, Santaguida S, Musacchio A, Knapp S

J. Med. Chem.. 2012-9-13 . 55(17):7841-8 .doi: 10.1021/jm3008954

PMID: 22920039

Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites.

Vidler LR, Brown N, Knapp S, Hoelder S

J. Med. Chem.. 2012-9-13 . 55(17):7346-59 .doi: 10.1021/jm300346w

PMID: 22788793

Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth.

Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honoré S, Aci-Sèche S, Grierson D, Antonipillai J, Li R, Di Pietro A, Dumontet C, Braguer D, Florent JC, Knapp S, Bernard O, Lafanechère L

Cancer Res.. 2012-9-1 . 72(17):4429-39 .doi: 10.1158/0008-5472.CAN-11-3342

PMID: 22761334

Fragment screening of cyclin G-associated kinase by weak affinity chromatography.

Meiby E, Knapp S, Elkins JM, Ohlson S

Anal Bioanal Chem. 2012-8-24 . 404(8):2417-25 .doi: 10.1007/s00216-012-6335-6

PMID: 22918538

Small-molecule inhibition of BRDT for male contraception.

Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE

Cell. 2012-8-17 . 150(4):673-84 .doi: 10.1016/j.cell.2012.06.045

PMID: 22901802

The bromodomain interaction module.

Filippakopoulos P, Knapp S

FEBS Lett.. 2012-8-14 . 586(17):2692-704 .doi: 10.1016/j.febslet.2012.04.045

PMID: 22710155